Literature DB >> 18078693

Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Erin Mehlhop1, Camilo Ansarah-Sobrinho, Syd Johnson, Michael Engle, Daved H Fremont, Theodore C Pierson, Michael S Diamond.   

Abstract

Severe dengue virus infection can occur in humans with pre-existing antibodies against the virus. This observation led to the hypothesis that a subneutralizing antibody level in vivo can increase viral burden and cause more severe disease. Indeed, antibody-dependent enhancement of infection (ADE) in vitro has been described for multiple viruses, including the flaviviruses dengue virus and West Nile virus. Here, we demonstrate that the complement component C1q restricts ADE by anti-flavivirus IgG antibodies in an IgG subclass-specific manner in cell culture and in mice. IgG subclasses that avidly bind C1q induced minimal ADE in the presence of C1q. These findings add a layer of complexity for the analysis of humoral immunity and flavivirus infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18078693      PMCID: PMC2194657          DOI: 10.1016/j.chom.2007.09.015

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  81 in total

1.  A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.

Authors:  Theodore C Pierson; Melissa D Sánchez; Bridget A Puffer; Asim A Ahmed; Brian J Geiss; Laura E Valentine; Louis A Altamura; Michael S Diamond; Robert W Doms
Journal:  Virology       Date:  2005-12-02       Impact factor: 3.616

Review 2.  Infections and allergy - helminths, hygiene and host immune regulation.

Authors:  Rick M Maizels
Journal:  Curr Opin Immunol       Date:  2005-09-30       Impact factor: 7.486

3.  PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons.

Authors:  Melanie A Samuel; Kevin Whitby; Brian C Keller; Anantha Marri; Winfried Barchet; Bryan R G Williams; Robert H Silverman; Michael Gale; Michael S Diamond
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection.

Authors:  Kamolwish Laoprasopwattana; Daniel H Libraty; Timothy P Endy; Ananda Nisalak; Supamit Chunsuttiwat; David W Vaughn; George Reed; Francis A Ennis; Alan L Rothman; Sharone Green
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

5.  Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Complement activation is required for induction of a protective antibody response against West Nile virus infection.

Authors:  Erin Mehlhop; Kevin Whitby; Theodore Oliphant; Anantha Marri; Michael Engle; Michael S Diamond
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  FcgammaRIV: a novel FcR with distinct IgG subclass specificity.

Authors:  Falk Nimmerjahn; Pierre Bruhns; Ken Horiuchi; Jeffrey V Ravetch
Journal:  Immunity       Date:  2005-07       Impact factor: 31.745

8.  Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus.

Authors:  Theodore Oliphant; Michael Engle; Grant E Nybakken; Chris Doane; Syd Johnson; Ling Huang; Sergey Gorlatov; Erin Mehlhop; Anantha Marri; Kyung Min Chung; Gregory D Ebel; Laura D Kramer; Daved H Fremont; Michael S Diamond
Journal:  Nat Med       Date:  2005-04-24       Impact factor: 53.440

9.  Structural basis of West Nile virus neutralization by a therapeutic antibody.

Authors:  Grant E Nybakken; Theodore Oliphant; Syd Johnson; Stephen Burke; Michael S Diamond; Daved H Fremont
Journal:  Nature       Date:  2005-09-29       Impact factor: 49.962

10.  Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

Authors:  Erin Mehlhop; Michael S Diamond
Journal:  J Exp Med       Date:  2006-05-01       Impact factor: 14.307

View more
  63 in total

Review 1.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation.

Authors:  Camilo Ansarah-Sobrinho; Steevenson Nelson; Christiane A Jost; Stephen S Whitehead; Theodore C Pierson
Journal:  Virology       Date:  2008-09-17       Impact factor: 3.616

Review 3.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

Review 4.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

5.  A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.

Authors:  Atsushi Yamanaka; Tomohiro Kotaki; Eiji Konishi
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

6.  Dengue Virus Induces Increased Activity of the Complement Alternative Pathway in Infected Cells.

Authors:  Sheila Cabezas; Gustavo Bracho; Amanda L Aloia; Penelope J Adamson; Claudine S Bonder; Justine R Smith; David L Gordon; Jillian M Carr
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

7.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Authors:  Erin Mehlhop; Steevenson Nelson; Christiane A Jost; Sergey Gorlatov; Syd Johnson; Daved H Fremont; Michael S Diamond; Theodore C Pierson
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

Review 8.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

Review 9.  Antibodies against viruses: passive and active immunization.

Authors:  Mansun Law; Lars Hangartner
Journal:  Curr Opin Immunol       Date:  2008-07-01       Impact factor: 7.486

10.  Alternative complement pathway deregulation is correlated with dengue severity.

Authors:  Eduardo J M Nascimento; Ana M Silva; Marli T Cordeiro; Carlos A Brito; Laura H V G Gil; Ulisses Braga-Neto; Ernesto T A Marques
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.